EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Utilization of Circulating Tumor DNA Testing in Biliary Tract Cancers

Michael Sheu, Nikolas Naleid, Omkar Pawar, Zhaohui Jin, Amit Mahipal

Current Oncology · 05.11.2026 · 33 (11) · 682

DOI: 10.3390/curroncol33110682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 05.11.2026. Verfasst von Michael Sheu und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumor DNA is a promising biomarker for molecular residual disease and recurrence surveillance in biliary tract cancers. We evaluated the association between postoperative tumor-informed ctDNA and recurrence-free survival (RFS) and assessed the performance of initial and longitudinal ctDNA surveillance.

Methods

We performed a single-institution retrospective cohort study of 51 patients with resected non-metastatic biliary tract cancers who underwent postoperative ctDNA testing. Kaplan–Meier, log-rank, univariable Cox regression, and limited multivariable Cox regression analyses were used to evaluate associations between ctDNA status and RFS. A 3-month landmark sensitivity analysis was performed to address time-related bias.

Results

Twenty-five patients (49.0%) developed recurrence. Recurrence occurred in 18 of 20 patients (90.0%) with postoperative ctDNA positivity compared with 7 of 31 patients (22.6%) without ctDNA positivity. Median RFS was 10.8 versus 47.4 months, respectively. Postoperative ctDNA positivity was associated with shorter RFS (HR, 7.85; 95% CI, 3.03–20.29; p < 0.001). In a pre-specified multivariable Cox model adjusting for stage III/IV disease and CA 19-9 > 37 U/mL, postoperative ctDNA positivity remained associated with shorter RFS (adjusted HR, 5.09; 95% CI, 1.82–14.26; p = 0.002). Longitudinal ctDNA surveillance demonstrated a sensitivity of 72.0%, specificity of 92.3%, PPV of 90.0%, and NPV of 77.4% for recurrence. Median lead time to recurrence was 69.5 days. In a 3-month landmark cohort of 37 evaluable patients, postoperative ctDNA positivity was associated with shorter subsequent RFS after exploratory adjustment for stage and CA 19-9 (adjusted HR, 6.45; 95% CI, 1.47–28.34; p = 0.014).

Conclusions

Postoperative ctDNA positivity was associated with recurrence and shorter RFS. Longitudinal ctDNA surveillance improved recurrence detection and frequently preceded clinically documented recurrence.

Zitieren

APA

Sheu, M., Naleid, N., Pawar, O., Jin, Z., & Mahipal, A. (2026). Utilization of Circulating Tumor DNA Testing in Biliary Tract Cancers. Current Oncology, 33(11), 682. https://doi.org/10.3390/curroncol33110682

Vancouver

Sheu M, Naleid N, Pawar O, Jin Z, Mahipal A. Utilization of Circulating Tumor DNA Testing in Biliary Tract Cancers. Current Oncology. 2026;33(11):682. doi:10.3390/curroncol33110682

BibTeX
@article{Sheu2026,
  author = {Sheu, Michael and Naleid, Nikolas and Pawar, Omkar and Jin, Zhaohui and Mahipal, Amit},
  title = {Utilization of Circulating Tumor DNA Testing in Biliary Tract Cancers},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {11},
  pages = {682},
  doi = {10.3390/curroncol33110682}
}
Kostenlos starten →